To study the role of Oxybutinin in infants affected with posterior urethral valve
Phase 3
- Conditions
- Health Condition 1: Q642- Congenital posterior urethral valves
- Registration Number
- CTRI/2023/08/056095
- Lead Sponsor
- Josy Thomas
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Infants with bladder dysfunction due to posterior urethral valve who have been adequately fulgurated.
Exclusion Criteria
Infants who have not undergone adequately fulgurated or who have undergone upper urinary tract diversion procedures.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method rodynamic study will be done to record voiding pressure, bladder volume with respect to age & bladder compliance.Timepoint: Urodynamic study will be done prior to administration of oxybutynin and 3 months after administration of oxybutynin.
- Secondary Outcome Measures
Name Time Method Clinical improvement Radiological improvement in bladder outline & upper renal tract UTI & efficacy/side effects of oxybutyninTimepoint: Baseline before starting oxybutynin & 3 months after starting oxybutynin.